If you're seeking MS care in Alabama, you can choose from five dedicated treatment centers across the state, including Tanner Center for Multiple Sclerosis and the UAB Center for Pediatric Onset Demyelinating Disease. Use this guide to compare regional options like the Univ of South Alabama Neuroimmunology and MS Clinic and local practices such as Alabama Neurology Associates and North Central Neurology Associates PC to find the right fit for your needs and life circumstances.
4 MS treatment centers14 active clinical trials8 providers with Medicare prescribing dataIncludes pediatric-focused center
Center types in Alabama
Academic MS Center (2)
Boutique MS Practice (1)
Dedicated MS Practice (1)
Filter by type:
50% of MS centers in Alabama are classified as Academic MS Center facilities.
Centers with Most Active Trials in Alabama
Ranked by active clinical trial count from ClinicalTrials.gov. Not a quality ranking.
Largest Care Teams in Alabama
MS Care by City
Active MS clinical trials in Alabama
See all 28 MS trials in Alabama →Active
Functional Outcomes From Diets in Multiple Sclerosis
University of Alabama at Birmingham
Birmingham
ActivePhase 4
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Novartis Pharmaceuticals
Birmingham · Cullman
ActivePhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Homewood
ActivePhase 3
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Novartis Pharmaceuticals
Birmingham
ActivePhase 3
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
Cullman
ActivePhase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Novartis Pharmaceuticals
Birmingham · Cullman
ActivePhase 3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
Cullman · Homewood


